文献速递前列腺癌

Decipher 1.0与1.1在局限性前列腺癌中的临床比较:前列腺切除与主动监测患者结果

Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients.
PubMed 文献 · Eur Urol Oncol · 2025-09-04

该研究在1579例局限性前列腺癌患者中比较Decipher v1.1与v1.0的临床预测效能,其中974例接受前列腺切除、605例进入主动监测。v1.1活检评分低于v1.0,且高v1.1评分与主动监测中活检升级风险升高相关,而v1.0无此关联;两版本高评分均与前列腺切除后复发风险升高相关。

要点

  • Decipher v1.1活检评分中位0.34,低于v1.0的0.45(p<0.01)。
  • 高v1.1评分(>0.6 vs <0.4)与主动监测中活检主要升级风险升高相关(HR 2.11,95%CI 1.14-3.89)。
  • v1.1与v1.0高评分均与前列腺切除后复发风险升高相关。

核心结论

  • Decipher v1.1评分倾向于低于v1.0,且能更好地预测主动监测中活检主要升级风险。
  • 两版本高评分均与前列腺切除后复发风险升高相关。

研究设计与样本

  • 回顾性机构队列数据库研究,共纳入1579例局限性前列腺癌患者。
  • 974例接受根治性前列腺切除,605例进入主动监测。
  • 双主要结局为主动监测后活检主要升级至Gleason分级组≥3和前列腺切除后复发。

主要发现

  • 活检Decipher v1.1评分中位0.34(IQR 0.22-0.50),低于v1.0的0.45(IQR 0.34-0.59),p<0.01。
  • 高Decipher v1.1评分(>0.6 vs <0.4)与主动监测中活检主要升级风险升高相关(HR 2.11,95%CI 1.14-3.89),v1.0无此关联。
  • 前列腺切除标本Decipher评分中位v1.0为0.64、v1.1为0.61。
  • v1.1和v1.0高评分均与前列腺切除后复发风险升高相关。

临床怎么用

  • 在主动监测决策中,可优先参考Decipher v1.1评分评估活检升级风险。
  • 前列腺切除后复发风险分层中,v1.0与v1.1高评分均可提供预后信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Decipher is a 22-gene genomic risk classifier that utilizes a whole-transcriptome microarray assay to provide a score ranging from 0 to 1. Recently, the individual gene scores that defined Decipher v1.0 were reweighted to define updated Decipher v1.1. Our objective was to assess the impact of that change in a large institutional cohort database with active surveillance (AS)- and radical prostatectomy (RP)-specific outcomes. The dual primary outcomes included a major biopsy upgrade to Gleason grade group ≥3 after AS and prostate cancer recurrence after RP. Of 1579 patients, 974 underwent RP and 605 enrolled on AS. Decipher v1.1 scores (median 0.34; interquartile range [IQR] 0.22, 0.50) were lower on biopsy than on Decipher v1.0 (median 0.45; IQR 0.34, 0.59; p < 0.01). A high Decipher v1.1 score was associated with a higher risk of a major biopsy upgrade on AS (>0.6 vs <0.4; hazard ratio 2.11 [95% confidence interval 1.14-3.89]), while Decipher v1.0 was not. The median Decipher scores on prostatectomy were 0.64 (v1.0) and 0.61 (v1.1). A high Decipher score was associated with a higher risk of recurrence after RP for both v1.1 and v1.0. In summary, Decipher v1.1 scores tend to be lower than those of Decipher v1.0 and better predict the risk of a major biopsy upgrade on AS.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Raizenne BL, Shee K, Cowan JE, et al. Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients. Eur Urol Oncol. 2025. PMID: 40908182. doi:10.1016/j.euo.2025.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。